No Data
shanghai allist pharmaceuticals co., ltd. (688578): Fomepizole continues to grow rapidly, reserves future pipeline for external cooperation.
Shanghai Allist Pharmaceuticals Co., Ltd. released the third quarter report for 2024, with the company achieving revenue of 2.53 billion yuan in Q1-Q3 of 2024, a year-on-year increase of +88%; net income attributable to mother was 1.06 billion yuan, a year-on-year increase of +159%; net income attributable to non-parent
Allist Pharmaceuticals' Q3 Profit Soars 101%, Operating Income Jumps 60%
shanghai allist pharmaceuticals co., ltd. (688578): Q3 revenue and profit both exceeded expectations, overseas clinical trials are about to make progress.
The company released its third quarter report, with Q1-3 revenue of 2.533 billion, yoy +87.97%; net profit attributable to shareholders of 1.063 billion, yoy +159%; with Q3 revenue alone at 0.957 billion, up by +59.73% year-on-year.
Shanghai Alice Pharmaceutical Technology Co., Ltd. Report for the Third Quarter of 2024
Express News | Shanghai Allist Pharmaceuticals Co., Ltd.: The net income for the first three quarters increased by 158.99% year-on-year.
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH): the net income in the first three quarters was 1.063 billion yuan, an increase of 158.99% year-on-year.
Gelonghui on October 24th announced the third quarter report of shanghai allist pharmaceuticals co., ltd. (688578.SH) for 2024, with the company's revenue for the first three quarters of 2.533 billion yuan, an 87.97% year-on-year increase; net income attributable to shareholders of the listed company of 1.063 billion yuan, a 158.99% year-on-year increase; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses of 1.011 billion yuan, a 165.98% year-on-year increase; and basic earnings per share of 2.36 yuan.
No Data
No Data